FrancophonIA/ELRC3.0 huggingface dataset:
English: Tepoxalin and its metabolites are highly protein-bound, more than 98%.
Maltese: Aktar minn 98% ta' Tepoxalin u l-metaboliti tagħha jabbinaw mal-proteini tad-demm.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTER {50 mg}{100 mg}{200 mg}
Maltese: TAGĦRIF MINIMU LI GĦANDU JIDHER FUQ IL-BLISTERS JEW L-ISTRIPS {50 mg}{100 mg}{200 mg}
English: • has had gastrointestinal ulceration or bleeding
Maltese: • għandu/ha allerġija għall-prodott
English: 100 mg / oral lyophilisate
Maltese: 100 mg / lajofiliżejt jittieħed mill-ħalq
English: 10 oral lyophilisates (EU/2/00/028/004) 30 oral lyophilisates (EU/2/00/028/005)
Maltese: 10 lajofiliżejt li jittieħdu mill-ħalq (EU/2/00/028/004) 30 lajofiliżejt li jittieħdu mill-ħalq (EU/2/00/028/005)
English: 200 mg / oral lyophilisate
Maltese: 200 mg / lajofiliżejt jittieħed mill-ħalq
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Maltese: Informazzjoni dettaljata dwar dan il-prodott tinstab fuq il-websajt ta' l-Aġenzija Ewropea għall-Mediċini (EMA) http://www.ema.europa.eu.
English: Oral administration of 10 mg tepoxalin / kg bodyweight results in inhibition of prostaglandin and leukotriene synthesis.
Maltese: Mediċina veterinarja li ma ġietx użata jew prodotti oħra li rriżultaw mill-użu ta' din il-mediċina għandhom jintremew skond kif titlob il-liġi tal-pajjiż.
English: 10 oral lyophilisates (EU/2/00/028/002) 30 oral lyophilisates (EU/2/00/028/003)
Maltese: 10 lajofiliżejt li jittieħdu mill-ħalq (EU/2/00/028/002) 30 lajofiliżejt li jittieħed mill-ħalq (EU/2/00/028/003)
English: A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH
Maltese: DIKJARAZZJONI TAS-SUSTANZA(I)
English: 50 mg / oral lyophilisate
Maltese: 50 mg / lajofiliżejt jittieħed mill-ħalq
English: If you notice any other side effects, please inform your veterinary surgeon.
Maltese: Kura fit-tul għandha dejjem issir taħt superviżjoni ta' veterinarju.
English: EU/2/00/028/005 (3 blisters)
Maltese: EU/2/00/028/005 (Tlett strixxi )
English: Zubrin oral lyophilisates for dogs
Maltese: U KONDIZZJONIJIET JEW RESTRIZZJONIJIET DWAR IL-PROVISTA
English: EU/2/00/028/003 (3 blisters)
Maltese: EU/2/00/028/003 (Tlett strixxi)
English: EU/2/00/028/007 (3 blisters)
Maltese: EU/2/00/028/007 (Tlett strixxi)
English: EXPIRY DATE EXP {month/year}
Maltese: PROJBIZZJONI TA' BEJGĦ, PROVISTA
English: MANUFACTURER'S BATCH NUMBER Batch {number}
Maltese: NUMRU TAL-LOT TAL-MANIFATTUR Lott {numru}
English: Pharmacotherapeutic group: Anti-inflammatory Products, Non Steroids ATCvet code: QM01AE92
Maltese: Prodotti kontra l-infjammazzjoni, mhumiex sterojdi.
English: Read the package leaflet before use.
Maltese: Mhux id-daqsijiet kollha tal-pakketti jistgħu jitpoġġew fis-suq.
English: Manufacturer for the Batch Release:
Maltese: Manifattur li jħalli l-konsenja tmur fis-suq:
English: NSAID overdosage is characterised by vomiting, soft faeces/diarrhoea, blood in faeces, reduced appetite and lethargy.
Maltese: Effetti tipiċi mhux mixtieqa u marbuta mal-użu ta' mediċini anti-infjammatorji li mhumiex sterojdi bħal remettar, ippurgar artab/sliħ, demm fl-ippurgar, nuqqas t'aptit, telqa u disturbi renali.
English: 6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Maltese: .8 Effetti fuq prodotti mediċinali oħra jew effetti oħra
English: 4.4 Special warnings
Maltese: 4.4 Twissijiet speċjali
English: If gastrointestinal bleeding is suspected, administer gastric protectants.
Maltese: Jekk wieħed jissuspetta telf ta' demm fis-sistema gastro-intestinali, għandhom jingħataw prodotti li jipproteġu l-istonku.
English: Peel back foil to reveal a single oral lyophilisate in the form of a round tablet.
Maltese: Qaxxar l-istrixxa biex tikxef sustanza waħda ta' lajofiliżejt, f'forma ta' pillola tonda.
English: MARKETING AUTHORISATION NUMBER(S) EU/2/00/028/006 (1 blister)
Maltese: NUMRU/I TA' L-AWTORIZZAZZJONI TAL-KUMMERĊ EU/2/00/028/006 (Strixxa waħda)
English: Tepoxalin must not be administered in conjunction with other NSAIDs or glucocorticosteroids, diuretics or anticoagulants.
Maltese: Tepoxalin m'għandhiex tingħata flimkien ma' mediċini anti-infjammatorji li mhumiex sterojdi jew mediċini kontra l-uġiegħ, glukokortikosterojdi, dijuretiċi jew antikoagulanti.
English: At doses of 30 mg/kg and above, oral administration of tepoxalin is associated with discoloured faeces ranging in colour from white to yellow, which is the result of unabsorbed drug.
Maltese: Mediċini anti-infjammatorji li mhumiex sterojdi, dijuretiċi, antikoagulanti u sustanzi li jabbinaw mal-proteini tad-demm f'ammonti kbar, jistgħu jikkompetu biex jabbinaw, u dan jista' jwassal għal effetti tossiċi.
English: Zubrin 200 mg oral lyophilisates for dogs
Maltese: VETERINARJU Zubrin 200 mg lajofiliżejt li jittieħed mill-ħalq, għall-klieb
English: MARKETING AUTHORISATION NUMBER(S) EU/2/00/028/002 (1 blister)
Maltese: NUMRU/I TA' L-AWTORIZZAZZJONI TAL-KUMMERĊ EU/2/00/028/002 (Strixxa waħda)
English: Otsuka Pharmaceutical Europe Ltd.Huton House Highbridge Busines Park, Oxford Road Uxbridge, Middlesex,
Maltese: TA`L-ISMIJIET, GĦAMLA FARMAĊEWTIKA, QAWWIET TAL-PRODOTTI MEDIĊINALI, MNEJN JINGĦATA, ID-DETENTURI TA`
English: EMA/741937/2015 EMEA/H/C/000477
Maltese: EMEA/H/C/000477
English: Aldurazyme laronidase
Maltese: Aldurazyme laronidażi
English: The full EPAR for Aldurazyme can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This summary was last updated in 11-2015.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'11-2015.
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 16 December 2015.
Maltese: Minħabba li lkumpanija kienet ipprovdiet l-informazzjoni addizzjonali mitluba, iċ-‘ċirkostanzi ta' eċċezzjoni' intemmew fis-16 ta' Diċembru 2015.
English: The active substance in Aldurazyme, laronidase, is a copy of the human enzyme α L iduronidase.
Maltese: Is-sustanza attiva f'Aldurazyme, il-laronidażi, hija kopja tal-enzima umana α L iduronidażi.
English: Aldurazyme was originally authorised under ‘exceptional circumstances', because, as the disease is rare, limited information was available at the time of approval.
Maltese: Aldurazyme kien oriġinarjament awtorizzat taħt “ċirkostanzi ta' eċċezzjoni”, għaliex minħabba li lmarda hija rari, kien hemm informazzjoni limitata disponibbli fi żmien l-approvazzjoni.
English: In children under five years of age, Aldurazyme reduced the levels of GAGs in the urine by about 60%.
Maltese: Fit-tfal ta' età inqas minn ħames snin, Aldurazyme naqqas il-livelli tal-GAGs fl-awrina b'madwar 60%.
English: The most common side effects in patients over the age of five years (seen in more than 1 patient in 10) are headache, nausea (feeling sick), abdominal pain (stomach ache), rash, arthropathy (damage to the joints), arthralgia (joint pain), back pain, pain in the extremities (hands and feet), flushing, pyrexia (fever) and reactions at the site of the infusion.
Maltese: L-effetti sekondarji l-aktar komuni fil-pazjenti ta' aktar minn ħames snin (li dehru f'aktar minn pazjent 1 minn 10) kienu wġigħ ta' ras, nawżja (dardir), uġigħ addominali (uġigħ fl-istonku), raxx, artropatija (ħsara lill-ġogi), artralġija (uġigħ fil-ġogi), uġigħ fiddahar, uġigħ fl-estremitajiet (idejn u saqajn), fwawar, piressija (deni) u reazzjonijiet fis-sit tal-infużjoni.
English: It is produced by a method known as ‘recombinant DNA technology': the enzyme is made by cells into which a gene (DNA) has been introduced that makes them able to produce laronidase.
Maltese: Jiġi prodott permezz ta' metodu magħruf bħala 'teknoloġija tad-DNA rikombinanti': l-enzima hi magħmula minn ċelloli li ġiet introdotta fihom ġene (DNA) li tagħmilhom kapaċi jipproduċu l-laronidażi.
English: This is a summary of the European public assessment report (EPAR) for Aldurazyme.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Aldurazyme.
English: Aldurazyme has also been studied in 20 children below the age of five years who received Aldurazyme for a year.
Maltese: Aldurazyme ġie studjat ukoll f'20 tifel u tifla ta' età inqas minn ħames snin, li ngħataw Aldurazyme għal sena.
English: Aldurazyme is a solution for infusion (drip) into a vein that contains the active substance laronidase.
Maltese: Aldurazyme huwa soluzzjoni għal infużjoni (dripp) fil-vina li fih is-sustanza attiva laronidażi.
English: Why has Aldurazyme been approved?
Maltese: Għaliex ġie approvat Aldurazyme?
English: Almost all patients who receive Aldurazyme develop antibodies (proteins that are produced in response to Aldurazyme).
Maltese: Kważi l-pazjenti kollha ttrattati b'Aldurazyme żviluppaw antikorpi (proteini prodotti bħala rispons għal Aldurazyme).
English: What is the risk associated with Aldurazyme?
Maltese: X'riskji huma assoċjati ma' Aldurazyme?
English: These were measured before and after 26 weeks of treatment.
Maltese: Dawn tkejlu qabel u wara 26 ġimgħa ta' trattament.
English: Aldurazyme is used in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; α L iduronidase deficiency) to treat the non-neurological symptoms of the disease (symptoms that are not connected with the brain or nerves).
Maltese: Aldurazyme jintuża f'pazjenti b'dijanjożi kkonfermata ta' mukopolisakkarodożi I (MPS I; defiċjenza ta' α L iduronidażi), għat-trattament tas-sintomi mhux newroloġiċi (sintomi mhux marbuta mal-moħħ jew man-nervituri) tal-marda.
English: In patients under five years of age, the most common side effects (seen in more than 1 patient in 10) are increased blood pressure, decreased oxygen saturation (a measure of how well the lungs are working), tachycardia (rapid heart rate), pyrexia and chills.
Maltese: Fil-pazjenti taħt l-età ta' ħames snin, l-effetti sekondarji l-aktar komuni (li dehru f'aktar minn pazjent 1 minn 10) kienu żieda fil-pressjoni tad-demm, tnaqqis tas-saturazzjoni tal-ossiġnu (kejl ta' kemm qed jaħdmu tajjeb il-pulmuni), takikardija (żieda fil-frekwenza tat-taħbit tal-qalb), piressija u tertir.
English: Aldurazyme has been compared with placebo (a dummy treatment) in 45 patients aged six years and over with a confirmed diagnosis of MPS I. The main measure of effectiveness was the forced vital capacity (FVC, a measure of how well the lungs are working) and the distance the patients could walk over six minutes.
Maltese: Aldurazyme tqabbel ma' plaċebo (trattament finta) f' 45 pazjent minn sitt snin' il fuq b' dijanjożi konfermata ta' MPS I.
English: MPS I is a rare, inherited disease, in which the level of α L iduronidase enzyme activity is much lower than normal.
Maltese: L-MPS I hija marda rari ereditarja, li fiha l-livell tal-attività enzimatika ta' α L iduronidażi huwa ferm iktar baxx min-normal.
English: What is Aldurazyme?
Maltese: Għal xiex jintuża Aldurazyme?
English: Aldurazyme treatment should be supervised by a doctor who has experience in the management of patients with MPS I or other inherited metabolic diseases.
Maltese: It-terapija b'Aldurazyme għandha tkun sorveljata minn tabib b'esperjenza fit-trattament ta' pazjenti b'MPS I jew mard metaboliku ereditarju ieħor.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Aldurazyme on 10 June 2003.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Aldurazyme valida fl-Unjoni Ewropea kollha fl-10 ta' Ġunju 2003.
English: Most of the side effects seen with Aldurazyme are reactions caused by the infusion procedure rather than the medicine itself.
Maltese: Il-maġġoranza tal-effetti sekondarji osservati b'Aldurazyme huma reazzjonijiet ikkawżati mill-proċedura ta' infużjoni aktar milli mill-mediċina stess.
English: How has Aldurazyme been studied?
Maltese: Kif ġie studjat Aldurazyme?
English: The CHMP decided that Aldurazyme gives effective control of the symptoms of MPS I. The Committee decided that Aldurazyme's benefits are greater than its risks and recommended that Aldurazyme be given marketing authorisation.
Maltese: Il-Kumitat iddeċieda li l-benefiċċji ta' Aldurazyme huma akbar mir-riskji tiegħu u rrakkomanda li Aldurazyme jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: Immediate packaging
Maltese: Daqs talPakkett
English: MA (EU) number (Invented) name
Maltese: Numru tal-UE Isem (ivvintat)
English: The full EPAR for Erbitux can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: EPAR summary for the public cetuximab
Maltese: Sommarju tal-EPAR għall-pubbliku cetuximab
English: The active substance in Erbitux, cetuximab, is a monoclonal antibody.
Maltese: Is-sustanza attiva f'Erbitux, cetuximab, hija antikorp monoklonali.
English: Between 79 and 89% of colorectal cancers and more than 90% of squamous cell cancers of the head and neck have EGFR on their cell surfaces.
Maltese: Bejn 79 u 89% tal-kanċers kolorettali u 'l fuq minn 90% taċ-ċelloli kanċiroġeni skwamużi fir-ras u fl-għonq ikollhom l-EGFR fil-wiċċ taċ-ċelloli tagħhom.
English: This is a summary of the European public assessment report (EPAR) for Erbitux.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Erbitux.
English: The most common side effects with Erbitux (seen in more than 1 patient in 10) are skin reactions such as rash, hypomagnesaemia (low blood magnesium levels), mild or moderate reactions linked to the infusion (such as fever, chills, dizziness and difficulty breathing), mucositis (inflammation of the lining of the mouth) and raised levels of some liver enzymes.
Maltese: L-effetti sekondarji l-aktar komuni b'Erbitux (li dehru f'aktar minn pazjent 1 minn kull 10) huma reazzjonijiet fil-ġilda bħar-raxx, ipomanjeżjemija (livelli baxxi ta' manjeżju fid-demm), reazzjonijiet ħfief jew moderati relatati mal-infużjoni (bħad-deni, tertir tal-bard, sturdament u diffikultà fit-teħid tan-nifs), mukożite (infjammazzjoni tar-rita tal-ħalq) u livelli għolja ta' xi enzimi tal-fwied.
English: Erbitux is a solution for infusion (drip into a vein) that contains the active substance cetuximab.
Maltese: Erbitux huwa soluzzjoni għall-infużjoni (dripp fil-vina) li fiha s-sustanza attiva cetuximab.
English: • two studies involved 1,535 patients who had not received chemotherapy before, looking at the effects of adding Erbitux to a treatment combination containing either irinotecan or oxaliplatin (FOLFOX); a third study looked also at the effects of adding Erbitux to two treatment combinations containing oxaliplatin (one of which was similar to FOLFOX) in 1,630 patients.
Maltese: • żewġ studji involvew 1,535 pazjent li ma kinux irċevew kemoterapija qabel, u ħarsu lejn leffetti li jiżdied Erbitux ma' trattament imħallat bl-irinotekan jew bl-oksaliplatin (FOLFOX4); ittielet studju ħares ukoll lejn l-effetti li jiżdied Erbitux ma' żewġ trattamenti mħallta bloksaliplatin (li wieħed minnhom kien simili għal FOLFOX4) f'1,630 pazjent.
English: • the second study involved 442 patients with recurrent or metastatic cancer, looking at the effects of adding Erbitux to a platinum-based anticancer medicine combination.
Maltese: • it-tieni studju involva 442 pazjent b'kanċer reċidiv jew metastatiku u ħares lejn l-effetti tażżieda ta' Erbitux ma' kombinazzjoni ta' mediċini kontra l-kanċer abbażi tal-platinu;
English: • together with anticancer treatments containing irinotecan;
Maltese: • flimkien ma' trattamenti kontra l-kanċer li fihom l-irinotekan;
English: • the first study involved 424 patients with locally advanced cancer, looking at the effects of adding Erbitux to radiotherapy;
Maltese: • l-ewwel studju involva 424 pazjent b'kanċer lokalment avvanzat u ħares lejn l-effetti taż-żieda ta' Erbitux mar-radjoterapija;
English: Why has Erbitux been approved?
Maltese: Għaliex ġie approvat Erbitux?
English: However, in the third study, patients with wild-type KRAS only survived overall for 16.3 months when Erbitux was added to the another oxaliplatin-based treatment similar to FOLFOX, compared with 18.2 months when the oxaliplatin-based treatment was used alone.
Maltese: Madankollu, fit-tielet studju, il-pazjenti bit-tip selvaġġ ta' KRAS għexu biss għal 16.3 xhur meta ġie miżjud Erbitux malkura l-oħra bbażata b'oksaliplatin simili għal FOLFOX, meta mqabbla ma' 18.2 xhur meta l-kura bbażata b'oksaliplatin intużat waħedha.
English: Before receiving Erbitux, the patient must be given an antihistamine and a corticosteroid to prevent an allergic reaction.
Maltese: Qabel jingħata Erbitux, il-pazjent irid jingħata antistamina u kortikosterojd sabiex tiġi evitata reazzjoni allerġika.
English: For metastatic cancer of the colon or rectum, Erbitux was studied in six main studies:
Maltese: Għal kanċer metastatiku tal-kolon jew tar-rektum, Erbitux ġie studjat f'sitt studji ewlenin:
English: Patients who had failed both oxaliplatin and irinotecan treatment lived for an average of 3.6 months without their disease getting worse with Erbitux, compared with 1.9 months in those receiving best supportive care alone (the treatment of symptoms but not the cancer itself).
Maltese: Ilpazjenti li fihom ma rnexxiex kemm it-trattament bl-oksaliplatin kif ukoll dak bl-irinotekan, b'Erbitux għexu medja ta' 3.6 xhur qabel mal-marda qalbet għall-agħar u 1.9 xhur f'dawk ittrattati bl-aqwa kura ta' appoġġ waħedha (it-trattament tas-sintomi iżda mhux il-kanċer innifsu).
English: Skin reactions are seen in more than 80% of patients.
Maltese: Irreazzjonijiet fil-ġilda dehru f'aktar minn 80% tal-pazjenti.
English: In cancer that is recurrent (when it has come back after previous treatment) or metastatic, Erbitux is used with a ‘platinum-based' anticancer medicine combination (including medicines such as cisplatin or carboplatin).
Maltese: Meta l-kanċer ikun reċidiv (meta jerġa' lura wara trattament preċedenti) jew metastatiku, Erbitux jintuża ma' taħlita ta' mediċini kontra l-kanċer abbażi tal-platinu (fosthom mediċini bħaċ-ċisplatinu jew il-karboplatinu)
English: What is Erbitux?
Maltese: Għal xiex jintuża Erbitux?
English: In locally advanced cancer (when the tumour has grown but has not spread), Erbitux is given in combination with radiotherapy (treatment with radiation).
Maltese: Filkanċer lokalment avvanzat (meta t-tumur ikun kiber iżda għadu ma nfirix), Erbitux jingħata flimkien mar-radjoterapija (trattament b'radjazzjoni).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Erbitux on 29 June 2004.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Erbitux fid-29 ta' Ġunju 2004.
English: • together with the oxaliplatin-containing treatment FOLFOX in patients who have not been treated before;
Maltese: • flimkien mat-trattament FOLFOX li fih l-oksaliplatin f'pazjenti li ma kinux ġew ikkurati qabel;
English: What is the risk associated with Erbitux?
Maltese: X'inhu r-riskju assoċjat ma' Erbitux?
English: EGFR is involved in switching on genes called RAS that are involved in the growth of cells; by attaching to EGFR, cetuximab prevents this from happening in the tumour cells and helps stop them growing.
Maltese: L-EGFR huwa involut fil-bidla tal-ġeni msejħa RAS li huma involuti fit-tkabbir taċ-ċelloli; billi jeħel mal-EGFR, cetuximab jipprevjeni dan milli jseħħ fiċ-ċelloli tat-tumur u jgħin biex iwaqqaf it-tkabbir tagħhom.
English: For cancers of the head and neck, Erbitux was investigated in two main studies:
Maltese: Għal kanċers fir-ras u fl-għonq, Erbitux ġie investigat f'żewġ studji ewlenin:
English: In locally advanced head and neck cancers, the patients lived for longer without their disease getting worse when Erbitux was added to radiotherapy (24.4 months compared with 14.9 months, on average).
Maltese: Fil-kanċers avvanzati lokalment fir-ras u fl-għonq, il-pazjenti għexu aktar mingħajr ma l-marda qalbet għall-agħar meta Erbitux żdied mar-radjuterapija (medja ta' 24.4 xhur meta mqabbla ma' 14.9 xhur).
English: Patients who had failed oxaliplatin treatment lived for an average of 4.0 months without their disease getting worse with Erbitux plus irinotecan, compared with 2.6 months in those receiving irinotecan alone.
Maltese: Ilpazjenti li fihom ma rnexxiex it-trattament bl-oksaliplatin, b'Erbitux flimkien mal-irinotekan għexu medja ta' 4.0 xhur mingħajr ma l-marda qalbet għall-agħar, meta mqabbla ma' 2.6 xhur ta' dawk li kienu qed jingħataw l-irinotekan weħidha.
English: Erbitux is used in patients whose tumour cells have a protein on their surface called epidermal growth factor receptor (EGFR) and contain ‘wild-type' (non-mutated) versions of a family of genes called ‘RAS'.
Maltese: Erbitux jintuża f'pazjenti li ċ-ċelloli tat-tumur tagħhom ikollhom proteina fuq il-wiċċ imsejħa riċettur tal-fattur tat-tkabbir epidermiku (EGFR) u fihom verżjonijiet slavaġ (mhux mutat) ta' familja ta' ġeni msejħa ‘RAS'.
English: Erbitux is given in the following ways:
Maltese: Erbitux jintuża f'dawn il-modi:
English: This summary was last updated in 12-2013.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'12-2013.
English: How has Erbitux been studied?
Maltese: Kif ġie studjat Erbitux?
English: These types of cancer affect the cells of the lining of the mouth or the throat, or of organs such as the larynx (voice box).
Maltese: Dawn it-tipi ta' kanċer jaffettwaw iċ-ċelloli tar-rita tal-ħalq jew tal-gerżuma, jew ta' organi bħal-larinġi (tal-vuċi).
English: Erbitux must not be used with oxaliplatin-containing chemotherapy for metastatic colorectal cancer in patients with mutated RAS or for whom RAS status is unknown.
Maltese: Erbitux jintuża wkoll fit-trattament ta' kanċers b'ċelloli skwamużi fir-ras u l-għonq.
English: Other information about Erbitux
Maltese: Kif jintuża Erbitux?
English: • in patients who had not received chemotherapy before, patients who had wild-type KRAS in their tumours lived for longer without their disease getting worse when they received Erbitux in addition to chemotherapy including irinotecan (9.9 months compared with 8.4 months, on average).
Maltese: • fil-pazjenti li ma kinux irċevew kemoterapija qabel, il-pazjenti bit-tip selvaġġ ta' KRAS fit-tumur tagħhom għexu iktar mingħajr ma l-marda qalbet għall-agħar meta ngħataw Erbitux flimkien malkemoterapija inkluż l-irinotekan (medja ta' 9.9 xhur meta mqabbla ma' 8.4 xhur). fil-pazjenti li rċevew Erbitux f'kombinazzjoni mal-oksaliplatin inkluża l-kemoterapija (FOLFOX) il-pazjenti bit-tip selvaġġ tar-RAS għexu aktar mingħajr ma l-marda qalbet għall-agħar meta mqabbla ma' pazjenti li rċevew FOLFOX waħdu (medja ta' 12.0 xhur meta mqabbla ma' 5.8 xhur).
English: United Kingdom Teva Uk Limited
Maltese: Teva Uk Limited
English: Capsule, Soft
Maltese: Kapsula, Soft
English: Coated Tablet
Maltese: Coated Pillola
English: Zentiva Italia Srl
Maltese: Italia Srl
English: United Kingdom Norton Healthcare Ltd T/A Ivax
Maltese: Norton Healthcare Ltd T/A Ivax
English: United Kingdom Noridem Enterprises Ltd Sodium Valproate Noridem Enterprises
Maltese: Noridem Enterprises Ltd Sodium Valproate Noridem Enterprises
English: Valproate Magnesium 10000mg/100 Ml
Maltese: Valproate Magnesium 10000mg/100
English: Pharma Gmbh Natriumvalproat G.L.
Maltese: G.L. Pharma Gmbh Natriumvalproat G.L.
English: Modified-Release Capsule, Hard
Maltese: Modified-Release Kapsula, Iebsa
English: United Kingdom Winthrop Pharmaceuticals Uk Ltd
Maltese: Winthrop Pharmaceuticals Uk Ltd
English: Pharma Gmbh Convulex Für Kinder
Maltese: G.L. Pharma Gmbh Convulex Für Kinder
English: Valproate Semisodium 269.1mg Tablet
Maltese: Valproate Semisodium 269.1mg Pillola
English: ácido Valpróico Generis Valproic Acid 400mg/4 Ml
Maltese: ácido Valpróico Generis Valproic Acid 400mg/4
English: Pharma Gmbh Convival Chrono
Maltese: G.L. Pharma Gmbh Convival Chrono
English: Valproate Semisodium 538.2mg Tablet
Maltese: Valproate Semisodium 538.2mg Pillola
English: Valproate 333mg Tablet
Maltese: Valproate 333mg Pillola